News | February 20, 2024
Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The agreement sets terms under which POC will manufacture the product or receive royalties
AIIMS Rewari is a 750-bed hospital complex which includes a 100 seat medical college, a 60 seat nursing college, a 30-bed AYUSH block
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
iSolveSM information on demand is the result of our focus on customer relationship
Launches collaborative centre for translational research in head and neck cancer
These re-agent and diagnostic test kits come with 99.7% accuracy
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Subscribe To Our Newsletter & Stay Updated
